default author photo

Du Shun-Da

Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital

1 Shuaifuyuan

Beijing, 100730

China

  • Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital

SCHOLARLY PAPERS

2

DOWNLOADS

66

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Patient-Reported Outcomes Regarding the Safety and Management of Immunotherapy in Primary Liver Cancer: A National Cross-sectional Study (CLEAP 005)

Number of pages: 24 Posted: 05 Nov 2025
Tang Yu-Hao, Du Shun-Da, Yang Xin-Rong, Peng Chuang, Liu Xiu-Feng, Guo Wen-Zhi, Gao Liang-Hui, Zhao Hai-Tao, Sun Hui-Chuan and Xu Li
Sun Yat-sen University (SYSU), Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Fudan University - Department of Liver Surgery, Central South University - Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital, Nanjing University - Nanjing Jinling Hospital, Zhengzhou University - Department of Hepatobiliary and Pancreatic Surgery, Hainan Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Liver Surgery, Fudan University - Department of Liver Surgery and Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China
Downloads 49 (1,097,529)

Abstract:

Loading...

Liver cancer, immunotherapy, adverse events, quality of life, patient-reported outcomes

2.

Gemcitabine-based chemotherapy plus PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors for initially unresectable intrahepatic cholangiocarcinoma: A multicenter, retrospective cohort study

Number of pages: 37 Posted: 08 Jun 2026
Xin Han, Haoliang He, Jinhuo Ding, Yixing Zhang, Zhigang Ren, Du Shun-Da, Jianwei Zhang, Hong-Kun Zhou, Chang-lin Zou, Xiaochang Wu, Zhiying Yang, Linping Dong, Xiaogang Dong, Qi Xu, Yang Huang, Hanqi Yu, Yufeng Zhong, Luhe Zhangbao, Jieer Ying, Weilin Wang, Zhongquan Sun and Yuan Ding
Zhejiang University - Department of Hepatobiliary and Pancreatic Surgery, Zhejiang University - Department of Hepatobiliary and Pancreatic Surgery, affiliation not provided to SSRN, Zhejiang University - Department of Hepatobiliary and Pancreatic Surgery, Zhengzhou University, First Affiliated Hospital, Department of Infectious Disease, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Jiaxing University - First Affiliated Hospital, Wenzhou Medical University, Huzhou Central Hospital, China-Japan Friendship Hospital - Department of Hepatobiliary Surgery, Zhejiang University, affiliation not provided to SSRN, Zhejiang Cancer Hospital, Zhejiang University - Department of Hepatobiliary and Pancreatic Surgery, Zhejiang University, affiliation not provided to SSRN, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Zhejiang University - Department of Hepatobiliary and Pancreatic Surgery, Zhejiang University - Department of Hepatobiliary and Pancreatic Surgery and Zhejiang University - Department of Hepatobiliary and Pancreatic Surgery
Downloads 17

Abstract:

Loading...

Intrahepatic cholangiocarcinoma, gemcitabine-based chemotherapy, PD-1/PD-L1 inhibitors, tyrosine kinase inhibitors, outcome.